Parkwoods Wealth Partners LLC Acquires New Stake in TG Therapeutics, Inc. (NASDAQ:TGTX)

Parkwoods Wealth Partners LLC bought a new position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor bought 7,001 shares of the biopharmaceutical company’s stock, valued at approximately $211,000. TG Therapeutics makes up approximately 0.2% of Parkwoods Wealth Partners LLC’s portfolio, making the stock its 29th largest position.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the company. The Manufacturers Life Insurance Company lifted its position in shares of TG Therapeutics by 3.7% during the second quarter. The Manufacturers Life Insurance Company now owns 80,664 shares of the biopharmaceutical company’s stock worth $1,435,000 after purchasing an additional 2,871 shares in the last quarter. Algert Global LLC increased its stake in TG Therapeutics by 193.8% during the 2nd quarter. Algert Global LLC now owns 147,218 shares of the biopharmaceutical company’s stock worth $2,619,000 after buying an additional 97,118 shares during the period. Creative Planning lifted its holdings in TG Therapeutics by 34.7% during the 2nd quarter. Creative Planning now owns 46,839 shares of the biopharmaceutical company’s stock worth $833,000 after buying an additional 12,076 shares in the last quarter. Quarry LP increased its position in shares of TG Therapeutics by 9.1% during the second quarter. Quarry LP now owns 6,003 shares of the biopharmaceutical company’s stock worth $107,000 after acquiring an additional 503 shares during the period. Finally, Point72 Asset Management L.P. acquired a new stake in shares of TG Therapeutics in the second quarter valued at $10,423,000. 58.58% of the stock is currently owned by hedge funds and other institutional investors.

TG Therapeutics Price Performance

TGTX stock opened at $33.70 on Wednesday. The company has a current ratio of 4.59, a quick ratio of 3.91 and a debt-to-equity ratio of 1.27. The company has a market capitalization of $5.25 billion, a P/E ratio of -335.72 and a beta of 2.24. The business has a 50 day simple moving average of $31.68 and a 200-day simple moving average of $26.36. TG Therapeutics, Inc. has a twelve month low of $12.84 and a twelve month high of $36.84.

TG Therapeutics (NASDAQ:TGTX) last issued its quarterly earnings results on Monday, November 4th. The biopharmaceutical company reported $0.02 earnings per share for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.01). The business had revenue of $83.90 million for the quarter, compared to analyst estimates of $81.68 million. TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. The firm’s revenue for the quarter was down 49.4% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.73 EPS. As a group, equities analysts anticipate that TG Therapeutics, Inc. will post 0.08 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the company. TD Cowen assumed coverage on TG Therapeutics in a research note on Tuesday, October 29th. They issued a “buy” rating and a $50.00 price objective for the company. The Goldman Sachs Group lifted their price target on shares of TG Therapeutics from $20.00 to $22.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 5th. StockNews.com raised shares of TG Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, January 7th. HC Wainwright reaffirmed a “buy” rating and set a $55.00 price objective on shares of TG Therapeutics in a research report on Wednesday, January 15th. Finally, JPMorgan Chase & Co. boosted their target price on shares of TG Therapeutics from $30.00 to $43.00 and gave the stock an “overweight” rating in a research note on Monday, November 25th. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $40.67.

Insider Buying and Selling

In other TG Therapeutics news, Director Sagar Lonial sold 5,000 shares of the business’s stock in a transaction on Monday, November 11th. The shares were sold at an average price of $30.44, for a total value of $152,200.00. Following the transaction, the director now directly owns 100,195 shares of the company’s stock, valued at approximately $3,049,935.80. The trade was a 4.75 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Sean A. Power sold 10,021 shares of the firm’s stock in a transaction on Monday, January 6th. The stock was sold at an average price of $28.53, for a total transaction of $285,899.13. Following the completion of the sale, the chief financial officer now owns 660,611 shares of the company’s stock, valued at $18,847,231.83. This trade represents a 1.49 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 26,358 shares of company stock valued at $781,497 over the last quarter. 10.50% of the stock is currently owned by insiders.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.